Ajman Bank Signs Strategic Financing Agreement with Life Pharma

Strategic Alliance to Boost Pharmaceutical Manufacturing

Ajman Bank has announced a strategic financing agreement with Life Pharma, the pharmaceutical manufacturing arm of VPS Healthcare, during the ‘Make in the UAE’ platform at the IHC pavilion. This collaboration signifies the UAE’s accelerating efforts to localize pharmaceutical industries and enhance its national production capabilities.

The partnership is part of a broader trend of increasing integration between national financial institutions and advanced manufacturing sectors, supporting the UAE’s objectives to establish a more resilient and sustainable industrial ecosystem capable of adapting to rapid changes in global supply chains.

Under this agreement, Life Pharma plans to implement its expansion strategies through significant investments in advanced manufacturing, product development, and the adoption of modern technologies. This reflects the vital role that national financial institutions play in enabling industrial growth and enhancing competitiveness.

Focus on Advanced Manufacturing and Innovation

Life Pharma is set to broaden its portfolio to include complex therapies, such as injectable formulations and specialized compositions, alongside acquiring and integrating intellectual property. These initiatives aim to bolster self-sufficiency, reduce reliance on imports, and establish the UAE as a regional hub for advanced pharmaceutical manufacturing.

Kashif Rizvi, Head of Corporate Banking at Ajman Bank, emphasized that this agreement underscores the bank’s ongoing commitment to empowering vital sectors that are essential for economic diversification and long-term resilience. Supporting advanced pharmaceutical manufacturing is a strategic priority, and through this partnership, we contribute to developing a high-value industrial ecosystem that aligns with national trends and meets future healthcare sector demands.

Madhukar Thana, CEO of Life Pharma, noted that the agreement comes at a pivotal moment for local manufacturing in the UAE, highlighting the importance of strategic partnerships in accelerating industrial capacity building, adopting advanced technologies, and enhancing access to vital treatments. Life Pharma continues to work on developing an advanced pharmaceutical platform capable of meeting both national and regional needs.

Long-Term Collaboration and Future Growth

This agreement coincides with the momentum generated by the ‘Make in the UAE’ platform, which continues to establish itself as a key driver for industrial investment and a supporter of pathways toward a more diversified and sustainable economy. The partnership also lays the groundwork for long-term collaboration, supporting expansion plans and future capabilities as Life Pharma’s operations grow.

This step aligns with Life Pharma’s rapid growth trajectory following the launch of its pharmaceutical facility in KIZAD, valued at AED 700 million. The collaboration reinforces the critical role of financing partnerships in empowering strategic industries and enhancing the UAE’s manufacturing landscape.

Frequently Asked Questions

What is the significance of the agreement between Ajman Bank and Life Pharma?

The agreement aims to enhance the UAE’s pharmaceutical manufacturing capabilities and support local production.

How will Life Pharma expand its portfolio?

Life Pharma plans to include complex therapies and acquire intellectual property to innovate in manufacturing.

What does this partnership mean for the UAE’s economy?

It signifies a commitment to diversifying the economy and enhancing industrial resilience.

What is the value of Life Pharma’s new facility?

Life Pharma’s new pharmaceutical facility in KIZAD is valued at AED 700 million.

How does this agreement align with national strategies?

The agreement supports the UAE’s objectives for a sustainable and diversified industrial ecosystem.